Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer

BMC Bioinformatics

Research

Yang Yu¹  Jiang Li¹  Dazhi Tian¹  Yanyan Sun¹  Zhaoxian Li² 

[1] Organ Transplant Center, Tianjin First Central Hospital, Nankai University, 300190, Tianjin, China;Organ Transplant Center, Tianjin First Central Hospital, Nankai University, 300190, Tianjin, China;School of Medicine, Nankai University, 94 Weijin Road, 300071, Tianjin, China;

关键词: XRCC4;    Pan-cancer;    Prognosis;    Immune;    Drug sensitivity;   

DOI  :  10.1186/s12859-023-05165-8

 received in 2022-07-26, accepted in 2023-01-30,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundXRCC4 is a NHEJ factor identified recently that plays a vital role in repairing DNA double-stranded breaks. Studies have reported the associations between abnormal expression of XRCC4 and tumor susceptibility and radiosensitivity, but the potential biological mechanisms by which XRCC4 exerts effects on tumorigenesis are not fully understood. This study aimed to systematically investigate the role of XRCC4 across cancer types.MethodsThe TIMER, GTEX and Xiantao Academic database were used to interpret the expression of XRCC4. Genomic alterations and protein expression in human organic and tumor tissues were applied in cBioPortal and the Human Protein Atlas databases. Correlations between XRCC4 expression and immune and molecular subtypes were analyzed by using the TISIDB database. Protein–protein interactions, GO and KEGG enrichment were also applied for XRCC4-related genes. The TIMER and the Tumor Immune Single Cell Hub (TISCH) online databases were used to explore the relationship between XRCC4 and tumor immune microenvironment. Drug sensitivity information was acquired from the CellMiner database to analyze the effect of XRCC4 on sensitivity analysis.ResultsThe XRCC4 expression was significantly upregulated in 15 tumor types and downregulated in two tumor types compared with the normal tissues, most of which were validated by the results of Xiantao academic platform. XRCC4 was expressed at intermediate level in malignant cells. The XRCC4 expression was related to the molecular and immune subtypes of human cancers, and the survival outcome of 11 types of cancers, including KIRC, STAD and LIHC. The main type of frequent genetic alteration is amplification. Strong correlations were also found between XRCC4 and immune checkpoint genes in 33 human cancers. Furthermore, the abnormal expression of XRCC4 was related to immune cell infiltration and drug sensitivity. Enrichment analysis showed that XRCC4 was significantly correlated with DNA damage response.ConclusionsThis comprehensive pan-cancer analysis suggested that XRCC4 may play a vital role in the prognosis and immunotherapy response in cancer patients, and it is a promising therapy target in the future.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

Fig. 1

13690_2023_1029_Article_IEq2.gif

Fig. 1

Fig. 8

Fig.6

Fig. 4

Fig. 6

Fig. 2

Fig. 4

Fig. 3

40854_2023_451_Article_IEq4.gif

Fig. 4

Fig. 6